Medically reviewed by Dr. Giovanni Scornavacca — Hair Restoration Specialist, Carisma Hair Clinic, St Julian's, Malta. 20+ years clinical experience, trained in Rome and Bologna.

Medically reviewed by Dr. Giovanni Scornavacca — Hair Restoration Specialist, Carisma Hair Clinic, St Julian's, Malta. 20+ years clinical experience.

Minoxidil Malta: A Complete Guide for Men and Women

Minoxidil is the most widely used topical hair loss treatment in the world. It is FDA-approved for both men and women, supported by decades of clinical evidence, and available in Malta in several formulations. What most people do not know is that choosing the right concentration, the right vehicle, and the right protocol makes a significant difference — and that most people who buy minoxidil off a pharmacy shelf are using it without that information.

This guide covers what minoxidil Malta patients need to know: how it works, what the evidence actually shows, and how to access the correct formulation for your specific pattern of hair loss.

Most men and women who research minoxidil do so privately, after noticing something they have been watching for months: a widening part, a hairline that looks different in certain light, a clump of hair in the shower that seems larger than it should be. You have done enough reading to know that minoxidil exists, but not enough to know whether it is right for you, which version to use, or what to reasonably expect. That is what this article addresses.

Minoxidil in Malta is accessible — but accessibility and appropriateness are different things. The right starting point is understanding exactly what this medication does, what it does not do, and where it fits within the broader landscape of hair loss treatment Malta options.

Contents

• ›What Is Minoxidil and How Does It Work?
• ›What the Evidence Shows: Efficacy and Realistic Expectations
• ›Minoxidil for Women: An Under-Recognised Option
• ›Minoxidil in Malta: What You Can Access and How
• ›Oral Minoxidil: The Growing Evidence Base
• ›The Maintenance Reality: What Minoxidil Does Not Tell You on the Packet
• ›Minoxidil Within a Combined Protocol
• ›The Malta-Specific Gap Most People Miss
• ›Frequently Asked Questions About Minoxidil in Malta

What Is Minoxidil and How Does It Work?

Minoxidil was originally developed as an oral antihypertensive medication — a blood pressure drug. During clinical trials in the 1970s, researchers observed a consistent and unexpected side effect: patients were growing hair. That observation eventually led to the development of a topical formulation specifically for hair loss, which was approved by the FDA in 1988 for men and 1991 for women.

It is important to understand what minoxidil is not. It is not a DHT blocker. It does not address the androgen-driven mechanism that causes male and female pattern hair loss at its root. Its mechanism of action is fundamentally different from finasteride, and understanding that distinction matters when you are deciding how to approach treatment.

Minoxidil works as a potassium channel opener. Applied topically to the scalp, it causes vasodilation — widening of the blood vessels that supply the dermal papilla, the structure at the base of each hair follicle responsible for nutrient delivery and signalling. By improving circulation to the follicle, minoxidil extends the anagen (active growth) phase of the hair cycle and shortens the telogen (resting) phase. Over time, this produces larger follicles, thicker individual hair shafts, and more hairs in the active growth phase at any given time.

The mechanism is well-established in its broad outline. The precise molecular pathway through which potassium channel opening translates into follicular stimulation is still not fully characterised — research continues — but the clinical effect is reproducible across thousands of patients in controlled trials. A topical minoxidil review published in PMC confirms the vasodilatory mechanism and anagen-phase extension as the most consistently supported pathways in peer-reviewed literature.

What this means in practical terms: minoxidil does not attack the cause of androgenetic hair loss. It works downstream, improving the environment in which surviving follicles operate. This is why it is most effective when used early, when follicles are still active, and why it works best as part of a combined protocol rather than as a standalone solution for most patients.

What the Evidence Shows: Efficacy and Realistic Expectations

The clinical evidence base for topical minoxidil is extensive. Clinical studies indicate that across multiple randomised controlled trials, approximately 60-70% of men using the treatment experience measurable improvement in hair density. In a 48-week randomised trial of 393 men, 74% showed improvement in hair density by independent investigator assessment. The minoxidil efficacy review on PubMed covering multiple controlled trials provides a thorough breakdown of these findings.

These are meaningful figures. They also require honest interpretation.

Minoxidil does not produce the same result in everyone, and the nature of the response varies. For some patients, the improvement is visible and significant — new terminal hairs where only vellus hairs existed. For others, the primary benefit is stabilisation: the hair loss that was progressing slows or stops. For a subset — approximately 30-40% of users — the response is limited. Results may vary for each individual, and pre-treatment prediction of response category is not reliably possible with current testing.

There is no pre-treatment test that can reliably predict which category you fall into. This is one of several reasons why initiating minoxidil under medical supervision, with baseline measurements and follow-up imaging, produces better outcomes than self-treating without benchmarks. Without objective measurement at baseline, it is difficult to assess whether treatment is working, particularly in the first several months when visible change is subtle.

The evidence for specific concentrations is clearer. A 48-week randomised trial comparing 5% and 2% formulations in men showed that the 5% produced approximately 45% more non-vellus hair regrowth than 2% (18.6 vs. 12.7 hairs added in the target area). For men, the 5% concentration is the standard and the clinically supported choice. For more on the specific evidence base around the stronger formulation, see the detailed guide on higher strength minoxidil 5%.

Regarding formulation — foam versus solution — both contain the same active ingredient at the same concentration. The foam formulation was developed primarily to reduce the scalp irritation caused by propylene glycol, a solvent used in the solution form. Both are considered equivalent in efficacy, with foam preferred by patients with scalp sensitivity or those who find the solution's texture inconvenient. If you are deciding between the two, the full comparison is covered in choosing between foam and solution.

Minoxidil for Women: An Under-Recognised Option

{width="940" height="650" loading="lazy"} Female pattern hair loss is significantly under-diagnosed — minoxidil is one of the few evidence-based options available for both sexes. Photo: www.kaboompics.com / Pexels

Female pattern hair loss affects approximately 40% of women by age 50, making it more common than most people realise. It tends to present differently from male pattern baldness: rather than frontal recession and vertex loss, women more commonly experience diffuse thinning across the crown, a widening central part, or overall reduction in density without a clearly defined pattern. It is also significantly under-diagnosed, partly because the presentation is more subtle, and partly because many women are told their hair loss is "stress-related" or dismissed without a clinical workup.

Minoxidil is one of very few licensed, evidence-based options for female hair loss. The FDA has approved it specifically for women, making it distinct from finasteride, which is contraindicated in women of childbearing age and only used off-label in post-menopausal women under specialist supervision.

The standard licensed formulation for women is 2% topical minoxidil, applied once or twice daily. Evidence suggests meaningful benefit in the majority of women treated, with improvement in hair density and a reduction in the rate of shedding. However, some women — particularly those with more pronounced thinning or who have not responded to 2% — may benefit from higher concentrations under medical guidance.

Minoxidil is particularly relevant for women experiencing:

• ›Female pattern hair loss (FPHL): Diffuse crown thinning and widening part, with or without a hormonal driver such as PCOS
• ›Postpartum hair shedding: The telogen effluvium that follows pregnancy can be severe; minoxidil may accelerate recovery once the acute shed phase has passed
• ›Diffuse thinning following nutritional or systemic causes: Once the underlying cause has been addressed, minoxidil can support regrowth during the recovery period

Women considering minoxidil should be assessed by a clinician before starting. The formulation, concentration, and whether oral or topical is more appropriate should be determined based on individual hair loss pattern, medical history, and any contraindications.

Minoxidil in Malta: What You Can Access and How

Malta has well-stocked pharmacies across the island, and minoxidil products are available without a prescription at lower concentrations. The practical landscape looks like this:

Over the counter: Topical minoxidil at 2% and 5% concentrations is typically available in major pharmacies without a prescription. You can purchase branded products such as Regaine (the primary European retail brand) in foam or solution formulations.

Prescription-only: Oral minoxidil — discussed in more detail below — requires a prescription from a licensed physician. Higher-concentration compounded topical formulations, where available, also require a prescription.

The distinction between buying minoxidil off the shelf and having a physician determine the correct protocol for your pattern is significant. The concentration, formulation, frequency of application, whether minoxidil should be combined with finasteride or another DHT-blocking approach, and how to interpret early shedding without stopping prematurely — these are clinical decisions, not packaging instructions.

Many patients who discontinue the treatment citing "it didn't work" stopped within the first 8-12 weeks, during the initial shedding phase that is a normal and expected part of how minoxidil works. Understanding what to expect from the minoxidil shedding phase before starting significantly improves adherence — and adherence is the primary determinant of whether the treatment succeeds.

A formal hair loss consultation in Malta gives you baseline scalp imaging, a clinical assessment of your pattern and stage, and a protocol built for your specific situation rather than the average patient described on a box insert.

Oral Minoxidil: The Growing Evidence Base

Oral minoxidil for hair loss is a relatively recent development in clinical practice, though the drug itself has been used in medicine for decades as a systemic antihypertensive. At the very low doses used for hair loss — typically 0.5 mg to 5 mg daily, compared with the 10-40 mg doses used for blood pressure — the mechanism is the same as topical: vasodilation and follicular stimulation.

The evidence base has grown substantially in recent years. A 2025 systematic review and meta-analysis covering 27 studies and 2,933 patients found that the majority of patients using low-dose oral minoxidil experienced improvement or stabilisation of hair loss. A 2024 randomised trial directly comparing oral and topical formulations found similar effects on hair growth outcomes, with oral achieving better patient compliance in practice. Clinical studies indicate that the low-dose oral form is an increasingly viable alternative for patients who struggle with consistent topical application.

The side effect profile of oral minoxidil differs from the topical form and requires careful consideration:

• ›Hypertrichosis (unwanted hair growth on the face, arms, and body) affects approximately 35% of users — the most commonly reported side effect
• ›Lower limb oedema (fluid retention) occurs in approximately 4% of users and may be clinically relevant in patients with cardiovascular or renal history
• ›Transient hypotension (a drop in blood pressure) is possible, though rare at the doses used for hair loss

Oral minoxidil is used off-label for hair loss — it is not licensed for this indication in most jurisdictions, including Malta. This means it must be prescribed by a physician who has assessed its suitability for the individual patient. It is not available over the counter.

For patients who have difficulty with consistent topical application, or who have not achieved satisfactory results with topical alone, oral minoxidil is an increasingly mainstream option. It is not appropriate for everyone, and the prescribing decision should be made by a clinician who understands your cardiovascular health, medication interactions, and hair loss pattern.

The Maintenance Reality: What Minoxidil Does Not Tell You on the Packet

This section matters more than most patients realise before they start.

Minoxidil does not cure hair loss. It modifies the environment in which hair follicles operate while you are using it. When you stop, the follicles return to their pre-treatment trajectory. The hair gained during treatment may be lost, typically within 6-12 months of discontinuation.

This is not a side effect or a failure of the medication. It is how the medication works — a continuous biological effect that requires continuous use to maintain. Studies show that approximately 60% of patients who used minoxidil for more than six months experienced significant recurrence within one year of stopping, and approximately 80% within two years. One study found that 40% of discontinuing patients had hair counts below their pre-treatment baseline after stopping — meaning they lost not only the gains but some of the ground they had been holding.

This is information worth having before you start, not after 18 months of treatment. It informs the decision to begin, and it underscores why minoxidil is most effectively used as part of a long-term clinical protocol rather than a time-limited trial.

For many patients, the question is not whether to use minoxidil indefinitely, but whether the results justify the commitment. A baseline-and-follow-up assessment at a specialist hair clinic provides objective data — not impression, not comparison to old photographs — that makes that decision considerably clearer.

Minoxidil Within a Combined Protocol

Minoxidil and finasteride work through entirely different mechanisms. Finasteride reduces DHT production at the follicle level — addressing the hormonal driver of androgenetic alopecia. The former improves the follicular environment by increasing blood supply and extending the growth phase. They are not alternatives to each other; for many patients, they are complementary.

A 2025 meta-analysis of seven randomised controlled trials confirmed that combination therapy — topical minoxidil plus finasteride — produces significantly greater improvements in hair density, hair diameter, and global photographic assessment than either treatment alone. This is now the standard recommendation in most specialist hair loss guidelines for appropriate candidates.

For patients who are interested in a comparison of the two medications before deciding where to start, the detailed breakdown is available in comparing finasteride with minoxidil.

Within the Hair Reset Protocol at Carisma Hair Clinic, minoxidil is one component of a structured 90-day non-surgical programme that may also include PRP (platelet-rich plasma) therapy and targeted nutritional support — all sequenced based on individual assessment findings from scalp imaging and density mapping. The clinical rationale is that each component addresses a different part of the hair loss pathway: DHT suppression, follicular stimulation, and regenerative signalling.

The Malta-Specific Gap Most People Miss

Malta has good pharmacy access to minoxidil. What is less available is the clinical infrastructure around it: baseline density measurement, formulation selection, ongoing monitoring, and protocol integration with other treatments.

The result is a predictable pattern. Patients buy minoxidil, start applying it once daily (the correct dose is twice daily for most formulations), experience the shedding phase that typically begins between weeks two and eight, conclude the medication is causing more hair loss, and stop — before the treatment has had time to work. Or they use it correctly for six months, see modest results, and do not know whether modest results represent a success or a non-response.

This is not a failure of minoxidil. It is a failure of context. The medication may work for the majority of patients who use it correctly, for long enough, at the right concentration, for the right pattern of hair loss. The gap is between a product on a pharmacy shelf and a clinical protocol.

For those who want to understand more about what the diagnostic process looks like before committing to treatment, the scalp imaging and density mapping approach used at Carisma Hair Clinic provides an objective baseline that makes treatment decisions — and treatment outcomes — considerably easier to interpret.

Frequently Asked Questions About Minoxidil in Malta

Is minoxidil available over the counter in Malta?

Yes. Topical minoxidil in 2% and 5% concentrations is available without a prescription at many pharmacies in Malta, typically under the brand name Regaine (foam and solution formulations). However, oral formulations and higher-concentration compounded products require a prescription from a licensed physician. Accessing minoxidil through a medical consultation rather than a pharmacy counter also gives you clinical guidance on the appropriate concentration, formulation, and protocol for your specific pattern of hair loss.

How much does minoxidil treatment cost in Malta?

Over-the-counter topical minoxidil (Regaine) typically costs between EUR 20-40 per month depending on the formulation and where it is purchased. A clinically supervised minoxidil protocol through a specialist hair clinic — which includes baseline scalp imaging, density mapping, and ongoing review — represents a higher initial investment but significantly better outcomes for most patients. Carisma Hair Clinic offers an initial consultation free of charge; treatment costs are discussed based on your individual protocol.

What is the difference between minoxidil 2% and 5%?

Concentration determines the magnitude of the effect. A 48-week randomised controlled trial showed that 5% minoxidil produced approximately 45% more non-vellus hair regrowth than 2% in men. The 5% formulation is the clinically recommended concentration for men. For women, 2% is the standard licensed concentration, though some women are assessed as candidates for 5% under physician guidance. The choice of concentration should be made with clinical input based on your hair loss pattern and history.

How long does minoxidil take to show results?

Visible improvement in density typically begins to appear at 3-6 months of consistent use, with more significant results at 9-12 months. Many patients notice increased shedding during the first 4-8 weeks — this is a recognised, temporary effect of the medication stimulating dormant follicles into the active growth phase. It is not a sign that treatment is failing. Stopping during this phase is a common reason minoxidil does not appear to work. Baseline scalp imaging makes it possible to track objective progress rather than relying on impression.

Can women use minoxidil for hair loss?

Yes. Minoxidil is FDA-approved for use in women and is one of very few evidence-based licensed treatments for female pattern hair loss. The standard licensed formulation for women is 2% topical minoxidil, though some physicians recommend 5% in appropriate cases. Women experiencing postpartum hair shedding, diffuse thinning, or PCOS-related hair loss may all be candidates. As with any treatment, the right formulation and dose should be determined by a clinician rather than selected independently. Results may vary for each individual.

What happens if you stop using minoxidil?

The hair gained during treatment may be lost within 6-12 months of stopping, as the follicles return to their pre-treatment trajectory. Studies show that approximately 60% of patients experience significant recurrence within one year of stopping, and around 80% within two years. Minoxidil is a continuous treatment — it modifies the follicular environment while in use. This is not a side effect; it reflects the mechanism of action. Patients should understand this commitment before starting rather than discovering it after discontinuation.

Is oral minoxidil safe for hair loss treatment?

Low-dose oral minoxidil has a growing evidence base for hair loss and is increasingly used in clinical practice. A 2025 systematic review covering 2,933 patients found the majority experienced improvement or stabilisation. The most common side effect is hypertrichosis (unwanted hair growth on the face and body), affecting approximately 35% of users. Lower limb oedema occurs in a smaller proportion. Oral minoxidil is used off-label for hair loss and requires a prescription. It is not appropriate for everyone — a physician assessment is essential before starting.

Do I need a prescription for minoxidil in Malta?

For standard topical minoxidil at 2% or 5%, no prescription is required in Malta — it is available over the counter at most pharmacies. The oral form and any compounded higher-strength formulations do require a prescription from a licensed physician. If you are considering oral minoxidil or a combination protocol involving prescription medications, a clinical consultation is necessary. A doctor will assess your medical history, cardiovascular health, and suitability before prescribing.

Ready to Take Control of Your Hair Loss?

If you have been researching your options and want a clinical assessment rather than another generic recommendation, Carisma Hair Clinic offers a comprehensive diagnostic consultation — scalp imaging, density mapping, and a personalised protocol designed around your specific pattern of loss.

→ Book Your Free Hair Loss Consultation

Dr. Giovanni Scornavacca and the team at Carisma Hair Clinic are available at our St Julian's clinic.

About the Author

Dr. Giovanni Scornavacca is a hair restoration specialist with over 20 years of clinical experience, with advanced training at universities in Rome and Bologna. He leads the Hair Reset Protocol at Carisma Hair Clinic — Malta's most complete non-surgical hair regrowth programme. Dr. Scornavacca specialises in diagnosing and treating androgenetic alopecia, telogen effluvium, and complex hair loss presentations using a combination of PRP, exosome therapy, and prescription protocols tailored to each patient.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Results may vary for each individual. Always consult a qualified healthcare professional before starting any hair loss treatment. Dr. Giovanni Scornavacca and Carisma Hair Clinic are available for clinical consultation at our St Julian's, Malta clinic.

Written and reviewed by Dr. Giovanni Scornavacca, Carisma Hair Clinic. Published: 26 June 2026.

Ready to Take Action?

Book a free consultation with Dr. Giovanni Scornavacca to get a personalised hair loss assessment and treatment plan.